Abstract
AimWe aim to evaluate the reproductive outcome of fertility-sparing surgery and chemotherapy among young women diagnosed with MOGCT of any stage.MethodsIn the current retrospective study we evaluated 79 patients with malignant ovarian germ cell tumors (MOGCT) who visited at Imam Center, Vali-e-asr Hospital, Gynecologic Oncology department during 2001–2016. Reproductive outcomes (menstruation status and childbearing) followed fertility-preserving surgery and adjuvant chemotherapy by filling questionnaires. Statistical analysis was done with SPSS software, Chi-Square Tests were done, and significance was determined at P ≤ 0.05. Results among 79 young women who underwent fertility-sparing treatment, 72 patients followed up for reproductive outcome, and 7 patients excluded because of death (3 cases), XY genotyping (3 cases), and bilateral ovarian involvement (1 case). The mean age at presentation was 23 years. (Range: 19–33 years). The 5 and 10-year disease-free survival rate was 87% and 94.4%, respectively. The overall survival rate (OSR) was 94.4% at 5 and 10 years. Regular menstruation recovered in 60 of 72 patients after treatment (83%). All patients without adjuvant chemotherapy experienced regular menstruation, while normal menstruation was retrieved in 78% in the adjuvant chemotherapy group at the end of treatment. This retrieval of regular menstruation was not dependent on the age or number of chemotherapy cycles. 19 of 26 patients who attempted pregnancy were led to delivery (73%). No one required infertility treatments. The mean of chemotherapy cycles is related to a successful pregnancy.ConclusionWe showed patients with MOGCT could become pregnant and give birth if they desire. The advanced tumor stage wasn't the convincing factor for avoiding fertility preservation. Fertility sparing surgery with adjuvant chemotherapy is a safe treatment and results in a high fertility rate.
Highlights
Malignant Ovarian Germ cell tumors (MOGCTs) are derived from primordial germ cells of the embryonic gonads
Impairment in ovarian function ovarian or premature ovarian failure is a risk of chemotherapy, most women who receive platinum-based therapy for three or four cycles retrieve regular ovarian function, and fertility is often spared in this group of patients [13,14,15,16,17,18,19,20]
We aim to evaluate the outcome and safety of fertility-sparing surgery (FSS) and chemotherapy among premenopausal women diagnosed with MOGCT of any stage
Summary
Malignant Ovarian Germ cell tumors (MOGCTs) are derived from primordial germ cells of the embryonic gonads. Most adult women who were diagnosed with MOGCT are recommended to undergo adjuvant chemotherapy. Several series have documented normal reproductive function without compromising survival following fertility-sparing surgery and chemotherapy [11, 12]. Impairment in ovarian function ovarian or premature ovarian failure is a risk of chemotherapy, most women who receive platinum-based therapy for three or four cycles retrieve regular ovarian function, and fertility is often spared in this group of patients [13,14,15,16,17,18,19,20]. The impact of platinum-based chemotherapy on adult women’s ovarian function was described in a representative series of 71 patients treated with fertility-sparing surgery and combination chemotherapy (including cisplatin and bleomycin). 62 (87%) regained normal menstruation, and 24 of these women eventually had 37 offspring [19]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
